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Oxidative damagedysfunction contributes to a range of important aspects of biomedical research.
Consequently there is considerable interest in developing approaches to modify and report on mitochondria
in cells and in vivo. One approach has been to target bioactive molecules to mitochondria by conjugating
them to lipophilic cations. Due to the large mitochondrial membrane potential, the cations are accumulated
within mitochondria inside cells. This approach had been used to develop mitochondria-targeted antioxi-
dants that selectively block mitochondrial oxidative damage and prevent some types of cell death and also to
develop probes of mitochondrial function. Here we outline some of the background to the development of
these compounds.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Mitochondria contribute to many aspects of cell function and
dysfunction. In particular, mitochondria are susceptible to oxidative
damage and are also a major source of superoxide, consequently
mitochondria accumulate oxidative damage contributing to mito-
chondrial dysfunction and cell death in a range of degenerative
diseases [1–4]. Despite this, antioxidants have had limited success in
preventing the progression of diseases involving mitochondrial
oxidative damage. One possible reason for this may be that most
small molecule antioxidants distribute around the body, with only a
small fraction being taken up by the mitochondria. Thus pharmaceu-
tically tractable and stable small molecule antioxidants are required
that are selectively taken up by mitochondria within those organs
most affected by mitochondrial oxidative damage where they block
oxidative damage. One approach to preventing mitochondrial oxida-
tive damage that may satisfy these criteria is to selectively target
antioxidants to mitochondria by conjugation to lipophilic cations such
as triphenyl phosphonium (TPP) [5–7] (Fig. 1).
The largemembranepotential of 150–180mV(negative inside) across
the mitochondrial inner membrane can be used to deliver molecules to
mitochondria [5]. Lipophilic cations pass easily through lipid bilayers
because their charge is dispersed over a large surface area and the
potential gradient drives their accumulation into the mitochondrial
matrix [8–11]. The uptake of lipophilic cations into mitochondria
increases 10 fold for every 61.5 mV of membrane potential at 37 °C
leading to 100–500 fold accumulation, anduptake into cells is alsodriven
by the plasma membrane potential (30–60 mV, negative inside) (Fig. 1).ll rights reserved.2. Mitochondria-targeted antioxidants
Awide range of antioxidants could be targeted to mitochondria by
conjugation to the TPP moiety, and those that have been employed to
date include TPP-conjugated derivatives of ubiquinone [12–15],
tocopherol [16], lipoic acid [17], spin traps [18] and the peroxidase
mimetic Ebselen [19]. As lipid peroxidation is important in many
forms of mitochondrial oxidative damage, and because the alkylTPP
conjugates strongly associate with the mitochondrial inner mem-
brane, the initial focus has been on antioxidants which are effective
against lipid peroxidation. In particular, the targeted version of
ubiquinol (MitoQ) has been used most extensively and is the best
understood member of the family (reviewed in [7]). To summarize the
work to date on MitoQ, it is taken up rapidly by isolated mitochondria
driven by the Δψ, and within mitochondria nearly all the accumulated
MitoQ is adsorbed to thematrix surface of the innermembrane. MitoQ
is reduced to the active ubiquinol antioxidant by complex II in the
respiratory chain, but it is not a good substrate for complex I or
electron transfer ﬂavoprotein-ubiquinone oxidoreductase. MitoQ
cannot restore respiration in mitochondria lacking coenzyme Q
because the reduced form of MitoQ is poorly oxidised by complex III;
consequently, all the effects of MitoQ are likely to be due to the
accumulation of the antioxidant ubiquinol form. Furthermore, when
the ubiquinol form of MitoQ acts as an antioxidant it is oxidised to the
ubiquinone form which is then rapidly reduced by complex II,
restoring antioxidant efﬁcacy. As MitoQ is largely found adsorbed to
the mitochondrial inner membrane, and its side chain enables it to
penetrate deeply into the membrane core, it was anticipated to be an
effective antioxidant against lipid peroxidation. This has been
conﬁrmed for isolated mitochondria. MitoQ has also been shown to
detoxify peroxynitrite and it can react with superoxide although,
as with other ubiquinols, its reactivity with hydrogen peroxide is
Fig. 1. Uptake of triphenylphosphonium cations by mitochondria within cells. This
schematic shows the uptake of a triphenylphosphonium moiety attached to a moiety
(X) into the cytoplasm from the extracellular environment driven by the plasma
membrane potential. From the cytoplasm the compound is further accumulated into
mitochondria, driven by the mitochondrial membrane potential. The mitochondrial and
plasma membrane potentials (Δψ) are indicated. The moiety, X, could be an antioxidant
or a probe of mitochondrial function.
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in isolated mitochondria, for a mitochondria-targeted antioxidant.
3. Targeting antioxidants to mitochondria in cells
In moving from isolated mitochondria to cells, toxicity is the ﬁrst
issue to be considered. The extensive accumulation of lipophilic
cations within isolated mitochondria can disrupt membrane integrity,
respiration and ATP synthesis as a result of adsorption of the lipophilic
cations to the matrix surface of the inner membrane. Supporting this
idea, the more hydrophobic TPP cations can disrupt mitochondrial
function at lower concentrations and the degree of disruption
correlates with the amount of compound adsorbed to the inner
membrane. The non-speciﬁc effects of MitoQ on mitochondria are
assessed using the control compound decylTPP which is similar in
hydrophobicity to MitoQ (octanol-PBS partition coefﬁcients of 5000
and 2760 respectively) but lacks the antioxidant ubiquinol moiety. We
ﬁnd that the non-speciﬁc mitochondrial disruption of MitoQ and
decylTPP occurs at similar concentrations and will always limit the
amounts of TPP-derived targeted antioxidants that can be used and
therefore it is essential that the compounds are effective antioxidants
at concentrations well below those that disrupt function.
In moving to cells from isolated mitochondria the targeted
antioxidants will be accumulated 5–10 fold relative to the extra-
cellular environment by the plasma membrane potential [10].
Consequently a given concentration of targeted antioxidant added to
the incubation will disrupt mitochondria in cells more than for
isolated mitochondria. In yeast, toxicity due to mitochondrial disrup-
tion can be assessed by observing the effects on cell growth on non-
fermentable medium. For mammalian cells in culture we ﬁnd that
concentrations in the range 0.1-1 µM generally avoid short-term
toxicity (unpublished observations). However this varies considerably
with cell density, type and incubation conditions and should be
checked for all new experimental arrangements.The uptake by MitoQ into cells is far faster than that of TPMP,
presumably due to its greater hydrophobicity lowering its activation
energy for passage through the plasma membrane [10]. MitoQ uptake
into cells is largely blocked by abolishing the mitochondrial
membrane potential by the uncoupler carbonylcyanide-p-triﬂuoro-
methoxyphenylhydrazone (FCCP), consistent with uptake being
primarily into the mitochondria and not to other cell compartments.
These data are consistent with rapid equilibration of MitoQ across
the plasma membrane followed by accumulation into mitochondria.
It is technically difﬁcult to conﬁrm that a lipophilic cation taken up by
cells is actually located within mitochondria as the mitochondria
depolarise and rapidly release the compounds during cell subfractio-
nation. An alternative way of visualizing TPP cations within cells is
by using the 4-iodobutyltriphenylphosphonium (IBTP) cation in
which TPP is linked to an iodoalkyl system that reacts with protein
thiols to form a stable thioether linkage [20]. This chemical bond
prevents loss of the functionalized TPP cation on cell ﬁxation and
the location can be visualized by using TPP-speciﬁc antiserum. The
results from these experiments indicate there is almost total
mitochondrial uptake within cells with very little remaining outside
the mitochondria [20]. This suggests that, in cells in culture, nearly
all accumulated lipophilic cations are present within mitochondria.
One further indication of the membrane potential-dependent mito-
chondrial concentration of TPP-containing molecules within cells
was the FCCP-sensitive protection afforded by MitoQ in a cell model
of Friedreich's ataxia, while FCCP did not affect the potency of decylQ
or idebenone [21]. This is fully consistent with MitoQ protecting
against the damage in this cell model due to its Δψ-dependent uptake
into mitochondria. Therefore on incubation with cells in culture,
MitoQ is predominantly accumulated within the mitochondria, but
the amount of MitoQ present throughout the cell is currently difﬁcult
to quantify.
MitoQ has been used in a large range of mitochondrial and cell
models [7], where they show protection against oxidative damage.
The interaction of MitoQ with mitochondrial ROS within rotenone-
treated ﬁbroblasts has been studied in detail [22]. MitoQ did not
decrease superoxide production as measured by dihydroethidium
oxidation but it did prevent lipid peroxidation as measured by the
ﬂuorescent probe C11-BODIPY [22]. This ﬁnding is consistent with the
model for MitoQ action developed from studies with isolated
mitochondria, namely that the main antioxidant action of MitoQ is
to prevent lipid peroxidation. It remains to be seen if this is the major
mechanism by which MitoQ acts as a protective agent in all cell types
and forms of oxidative stress.
4. Targeting antioxidants to mitochondria in vivo
To function as therapies mitochondria-targeted antioxidants must
be delivered to mitochondria within cells in patients, preferably
following oral administration. As TPP cations pass easily through
phospholipid bilayers they should be able to pass from the gut to the
bloodstream and from there to most tissues. It has been shown that
when simple alkylTPP compounds, MitoE or MitoQ are administered
to mice by intravenous injection they are rapidly cleared from the
plasma and accumulate in the heart, brain, skeletal muscle, liver and
kidney [23]. These experiments clearly indicate that once in the
bloodstream alkylTPP compounds rapidly redistribute into organs.
Importantly, TPP-derived compounds are orally bioavailable to
mice, as was shown by feeding mice tritiated TPMP, MitoE or MitoQ in
their drinking water which led to uptake into the plasma and from
there into the heart, brain, liver, kidney and muscle [23]. The TPMP
was shown to be cleared from all organs at a similar rate by a ﬁrst
order process with a half life of about 1.5 days [23]. Therefore these
studies are consistent with orally-administered alkylTPP compounds
distributing to all organs due to their facile permeation through
biological membranes.
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and cells will also occur in vivo and this will probably be the major
factor limiting the amounts of the compound that can be administered
safely. In crude toxicity assessments [23] TPMP and MitoE showed no
toxicity at 300 nmol intravenous (~4–6 mg/kg) but did show toxicity
at 500 nmol (~6–10 mg/kg). MitoQ was marginally better tolerated
with no toxicity at 750 nmol (~20 mg/kg) but toxicity evident at
1,000 nmol (~27 mg/kg). Administering 500 M TPMP, MitoE or MitoQ
tomice in their drinking water could bemaintained for several weeks:
no toxic effects were noted for TPMP for at least 43 days, MitoE for at
least 14 days or MitoQ for at least 14 days [23]. The similarities in
toxicities are consistent with the hypothesis that the toxic effects are
largely due to non-speciﬁc disruption to mitochondria caused by
accumulation of large amounts of the lipophilic cation. To summarize,
it is possible to administer alkyltriphenylphosphonium compounds to
animals orally and they are taken up into the plasma with reasonable
bioavailability and then rapidly cleared from the plasma accumulating
in mitochondria within tissues.
Having shown that the long-term administration of mitochondria-
targeted antioxidants is possible, the next step is to determine
whether the amount of compound accumulated is sufﬁcient to act as
an antioxidant in vivo. When 500 µM MitoQ was administered to rats
in their drinking water for 2 weeks and the hearts then isolated and
exposed to ischemia–reperfusion injury in a Langendorff perfusion
system there was protection against the loss of heart function, tissue
damage and mitochondrial function compared with TPMP or short
chain quinol controls [24]. The most probable reason for the observed
protection in these experiments is that lipid peroxidation in the
mitochondrial inner membrane was being prevented by MitoQ [24].
However, this has yet to be conﬁrmed by showing that MitoQ can
block an increase in markers of oxidative damage in mitochondria. In
another work, MitoQ protected against oxidative damage caused by
nitroglycerin in the rat aorta [25]. Therefore there is evidence that
mitochondria-targeted antioxidants may be effective in vivo.
The development of MitoQ as a pharmaceutical is somewhat
different from that of most other pharmaceuticals. Typically, in
medicinal chemistry a large number of compounds are investigated
that are based on a lead compound that interacts with a speciﬁc target,
such as a receptor binding site. In assessing these compounds, the
“rule of ﬁve” is often used as a preliminary screen to ensure that drug
candidates are soluble, bioavailable and can pass through phospho-
lipid bilayers [26]. However mitochondria-targeted antioxidants
based on TPP lipophilic cations are less constrained by these
traditional guidelines as they have the unusual property of being
both relatively water soluble and membrane permeant. Even though
the molar mass of MitoQ is relatively large for a pharmaceutical and it
has a high octanol/PBS partition coefﬁcient, it is readily bioavailable
and passes easily through biological membranes. A further unusual
feature of the TPP-targeted compounds is that they are targeted to an
organelle to interfere in a general rather than a speciﬁc process, viz
oxidative damage. Therefore if lipophilic cations such as MitoQ prove
to be effective pharmaceuticals it represents an unusual approach to
medicinal chemistry and drug discovery. MitoQ is now being
developed as a pharmaceutical by Antipodean Pharmaceuticals Inc.
(http://www.antipodeanpharma.com/).
5. Conclusions
The use of the TPP cation to increase the antioxidant defences of
mitochondria has been demonstrated to be a viable strategy in vitro. It
has also been shown that compounds such as MitoQ can be formed
into pharmaceuticals that can be successfully delivered orally to
humans. Animal experiments have indicated that MitoQ has anti-
oxidant efﬁcacy in tissues and therefore the scene is set for testing this
and related compounds in human diseases. It will be important to
ascertain deﬁnitively whether these chemicals are acting as effectiveantioxidants in vivo and whether by so doing they improve the
outcome of the disease pathology. An intriguing aspect of the use of
mitochondria-targeted antioxidants is that they could in principle be
applied to a range of diseases and organs, because mitochondrial
oxidative damage contributes to so many disorders. Hopefully work
over the next few years will indicate in which organs these
compounds are effective, whether they can decrease mitochondrial
oxidative damage in diseases, and whether this positively affects the
outcome for the patient. In addition there is considerable potential to
use these compounds to act as probes for mitochondrial ROS
production and oxidative damage and to manipulate and report on
mitochondrial function in a number of ways.
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